Synthesis of Adagrasib (MRTX849), a Covalent KRAS(G12C) Inhibitor Drug for the Treatment of Cancer

[Image: see text] A concise, transition-metal and protection-free synthesis of adagrasib (MRTX849), a novel KRAS(G12C) inhibitor drug recently approved by the FDA, is reported. Introduction of two chiral building blocks to the tetrahydropyridopyrimidine core was accomplished via two sequential S(N)A...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Cheng-yi, Lu, Zhichao, Scattolin, Thomas, Chen, Chengsheng, Gan, Yonghong, McLaughlin, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942190/
https://www.ncbi.nlm.nih.gov/pubmed/36723667
http://dx.doi.org/10.1021/acs.orglett.2c04266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942190/
https://www.ncbi.nlm.nih.gov/pubmed/36723667
http://dx.doi.org/10.1021/acs.orglett.2c04266

Ejemplares similares